UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.706-713

2010

Link zum Volltext

Verfügbarkeit prüfen

A novel strategy for physiologically based predictions of human pharmacokinetics

Clinical pharmacokinetics, 2006-01, Vol.45 (5), p.511-542

2006

Link zum Volltext

Verfügbarkeit prüfen

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Clinical pharmacology and therapeutics, 1995-05, Vol.57 (5), p.508-517

1995

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Clinical cancer research, 2011-04, Vol.17 (8), p.2512-2520

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa

British journal of clinical pharmacology, 1995-09, Vol.40 (3), p.253-262

1995

Link zum Volltext

Verfügbarkeit prüfen

562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex

Annals of oncology, 2020-09, Vol.31, p.S484-S485

2020

Link zum Volltext

Verfügbarkeit prüfen

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Journal of neurology, 1998-04, Vol.245 (4), p.223-230

1998

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

European journal of clinical pharmacology, 1998-07, Vol.54 (5), p.443-447

1998

Link zum Volltext

Verfügbarkeit prüfen

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.300-310

1997

Link zum Volltext

Verfügbarkeit prüfen

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

Clinical pharmacology and therapeutics, 1998-06, Vol.63 (6), p.646-654

1998

Link zum Volltext

Verfügbarkeit prüfen

Effect of Tolcapone on the Haemodynamic Effects and Tolerability of Desipramine

European neurology, 2000-01, Vol.44 (2), p.94-103

2000

Link zum Volltext

Verfügbarkeit prüfen

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.544-551

2000

Link zum Volltext

Verfügbarkeit prüfen

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

British journal of clinical pharmacology, 1999-09, Vol.48 (3), p.449-452

1999

Link zum Volltext

Verfügbarkeit prüfen

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

European journal of clinical pharmacology, 1996, Vol.50 (1-2), p.47-55

1996

Link zum Volltext

Verfügbarkeit prüfen

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

Clinical neuropharmacology, 1997-12, Vol.20 (6), p.531-541

1997

Link zum Volltext

Verfügbarkeit prüfen

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

British journal of clinical pharmacology, 2001-09, Vol.52 (3), p.255-264

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

Neurology, 1998-05, Vol.50 (5 Suppl 5), p.S31

Jorga, K M

1998

Link zum Volltext

Verfügbarkeit prüfen

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

British journal of clinical pharmacology, 1999-10, Vol.48 (4), p.513-520

1999

Link zum Volltext

Verfügbarkeit prüfen

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13009-e13009

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2558-2558

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

Clinical neuropharmacology, 2000-03, Vol.23 (2), p.98-105

2000

Link zum Volltext

Verfügbarkeit prüfen

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

European journal of clinical pharmacology, 2001-05, Vol.57 (2), p.115-121

2001

Link zum Volltext

Verfügbarkeit prüfen

609 Predicting response and anaemia in HCV genotype 1 patients treated with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): A generalised additive logistic model (GAM) analysis

Journal of hepatology, 2006-04, Vol.44, p.S226-S226

2006

Link zum Volltext

Verfügbarkeit prüfen

616 Population pharmacokinetic analysis of ribavirin (COPEGUS®) after single and multiple dose administration in adult chronic hepatitis C (CHC) patients receiving concurrent peginterferon alpha-2a (40KD) (PEGASYS®)

Journal of hepatology, 2006-04, Vol.44, p.S229-S229

2006

Link zum Volltext

Verfügbarkeit prüfen

Response to Garrido et al.: "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits"

Clinical neuropharmacology, 1996-02, Vol.19 (1), p.98-99

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Humans
(31)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Pharmacology. Drug Treatments
(26)
Male
(25)
Pharmacology & Pharmacy
(21)
Nitrophenols
(20)
Adult
(18)
Anticonvulsants. Antiepileptics. Antiparkinson Agents
(17)
Neuropharmacology
(17)
Tolcapone
(16)
Female
(15)
Middle Aged
(13)
Pharmacokinetics
(13)
Benzophenones - Pharmacokinetics
(12)
Benzophenones - Pharmacology
(12)
Catechol O-Methyltransferase Inhibitors
(11)
Aged
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

A novel strategy for physiologically based predictions of human pharmacokinetics

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa

562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

Effect of Tolcapone on the Haemodynamic Effects and Tolerability of Desipramine

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects

A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin : comparison of the effect in healthy volunteers and in HIV-infected patients

609 Predicting response and anaemia in HCV genotype 1 patients treated with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): A generalised additive logistic model (GAM) analysis

616 Population pharmacokinetic analysis of ribavirin (COPEGUS®) after single and multiple dose administration in adult chronic hepatitis C (CHC) patients receiving concurrent peginterferon alpha-2a (40KD) (PEGASYS®)

Response to Garrido et al.: "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits"

Suchergebnisse filtern